Cegedim S.A.

Cegedim is a technology and services company. Co. supplies services, IT tools, specialized software, information flow and database management services to healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies. Co.'s operations can be divided into three sectors: CRM and Strategic Data (optimizing marketing and sales strategies, namely through tools and databases for managing sales forces, returns on investment, market or prescriber studies); Healthcare Professionals (software publishing with availability of promotional information) and Insurance and Services (software publishing and management of healthcare reimbursement flows).
  • TickerCGM
  • ISINFR0000053506
  • ExchangeEuronext Paris
  • SectorSoftware & Computer Services
  • CountryFrance

Cegedim: 1 director sold

A director at Cegedim sold 1,000 shares at 27.332EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Cegedim: 1 director sold

A director at Cegedim sold 1,000 shares at 27.332EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Geoffroy Michalet

Cegedim : H1 2020 organic sales held up well

>H1 sales: rather satisfactory - Yesterday evening Cegedim reported rather satisfactory Q2 and H1 sales. While we expected an organic contraction of -2.0% in H1, the drop came to -2.5% LFL (-3.9% reported) due notably to changes to the consolidation scope at -1.4% owing to the disposal of Pulse in the US (doctors) and the acquisitions of NetEDI (E-Business) and Cosytec (HR). Forex did not have an impact on H1.By division:Health Insurance, HR & E-Services (68...

Geoffroy Michalet

Cegedim : CA S1 2020, bonne résistance de l’organique

>CA S1 : plutôt de bonne facture - Cegedim a publié hier soir son CA T2 et S1, plutôt de bonne facture. Alors que nous attendions un S1 en baisse organique de -2.0%, il ressort à -2.5% org, et -3.9% en publié, notamment avec un effet périmètre de -1.4% du fait de la cession de Pulse aux USA (médecins) et des acquisitions de NetEDI (E-Business) et Cosytec (RH). Le FX n’a pas d’impact sur le semestrePar division :Health Insurance, HR & E-Services (68% du CA) :...

Geoffroy Michalet

Cegedim : Favourable positioning, but short-term potential priced in

Cegedim is a diversified SaaS software and services group. It has historically worked with healthcare professionals (77% of revenues) but is also present in other areas of expertise, such as insurance, BPO, EDI and RH. The group boasts a COVID-resilient profile and opportunity-rich business operations, with 77% of revenues exposed to the healthcare sector. That said, its modest cash generation capacity has already been factored in. We are initiating coverage of the stock with a N...

Geoffroy Michalet

Cegedim : Un positionnement prometteur, mais un potentiel court terme bien valorisé

Groupe diversifié de logiciels en SaaS et de services, Cegedim opère historiquement auprès d’une clientèle de praticiens de santé mais est également présent sur d’autres expertises (Assureurs, BPO, EDI, RH…). Exposé à 77% de son CA au domaine de la santé, il présente un profil résilient au COVID-19 et des activités porteuses d'opportunités. Mais sa génération de cash modeste nous parait bien valorisée. Nous initions à Neutre avec un objectif de 34.0 €. - >Des métiers diver...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior